GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GRI GRI BIO INC

Trading 07-02 10:39:35 EDT

1.85

+0.07

+3.93%

High1.86	Low1.80	Vol16.10K
Open1.82	D1 Closing1.78	Amplitude3.13%
Mkt Cap3.28M	Tradable Cap912.98K	Total Shares1.77M
T/O29.69K	T/O Rate3.26%	Tradable Shares493.50K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GRI","market":"US","secType":"STK","nameCN":"GRI BIO INC","latestPrice":1.85,"timestamp":1783002617718,"preClose":1.78,"halted":0,"volume":16095,"delay":0,"changeRate":0.03932584269662925,"floatShares":493500,"shares":1770838,"eps":-87.4667,"marketStatus":"Trading","change":0.07,"latestTime":"07-02 10:39:35 EDT","open":1.82,"high":1.86,"low":1.8043,"amount":29688.791934,"amplitude":0.031292,"askPrice":1.88,"askSize":185,"bidPrice":1.82,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-87.4667,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783022400000},"marketStatusCode":2,"symbolChange":{"newSymbol":"RDOG","executeDate":"2020-01-02"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.78,"sharesOutstanding":1100000,"nav":47.93,"aum":52503274.57,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":1.83,"preClose":1.78,"latestTime":"09:25 EDT","volume":1842,"amount":3430.394361,"timestamp":1782998703285,"change":0.05,"changeRate":0.02809,"amplitude":0.159944},"postHourTrading":{"tag":"盘后","latestPrice":1.7635,"preClose":1.78,"latestTime":"19:53 EDT","volume":573,"amount":1011.657,"timestamp":1782949992347,"change":-0.0165,"changeRate":-0.00927,"amplitude":0.00927},"volumeRatio":1.398933},"requestUrl":"/m/hq/s/GRI/tweets","defaultTab":"tweets","newsList":[{"id":"2644085843","title":"GRI Bio wins FDA orphan drug designation for GRI-0621 in pulmonary fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085843","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085843?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785908,"startTime":"0","endTime":"0","summary":"FDA granted orphan drug designation to GRI-0621  for idiopathic pulmonary fibrosis.Designation could support 7 years of US market exclusivity if the drug wins approval.GRI-0621 is a once-daily oral RARβ/γ-selective agonist evaluated in a Phase 2a trial in 35 patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1dpCH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014005.SGD","SG9999014039.USD","LU2210149790.SGD","BK4007","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","LU2210150020.SGD","BK4112","GRI","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083041","title":"GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083041?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:31","pubTimestamp":1781785860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUAC4S9HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742088","title":"GRI Bio granted FDA orphan designation for tazarotene","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742088","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644742088?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:00","pubTimestamp":1781708410,"startTime":"0","endTime":"0","summary":"GRI Bio’s (GRI) tazarotene was granted FDA orphan designation as a treatment of idiopathic pulmonary fibrosis, according to a post to the agency’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gri-bio-granted-fda-orphan-designation-for-tazarotene-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gri-bio-granted-fda-orphan-designation-for-tazarotene-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRI","LABU","BK4588","BK4007","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642458122","title":"Grupo Aeroportuario del Pacifico Publishes its 2025 Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2642458122","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642458122?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:58","pubTimestamp":1780966680,"startTime":"0","endTime":"0","summary":"GUADALAJARA, Mexico, June  08, 2026  (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces the publication of its2025 Sustainab","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308511/0/en/Grupo-Aeroportuario-del-Pacifico-Publishes-its-2025-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4174","ESG","BK4139","BK4094","GRI","BK4585","ISSB","GAP","PAC","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157582","title":"Aya Gold & Silver Releases its 2025 Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157582","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157582?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574400,"startTime":"0","endTime":"0","summary":"MONTREAL, June  04, 2026  (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Company”) is pleased to announce the publication of its 2025 Sustainability Report for the y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306697/0/en/Aya-Gold-Silver-Releases-its-2025-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SETM","AYA","BK4210","ESG","BK4007","BK4139","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640063489","title":"Moody's Rates Danantara Investment at Baa2","url":"https://stock-news.laohu8.com/highlight/detail?id=2640063489","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640063489?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:03","pubTimestamp":1780477399,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -Global rating agency Moody's Ratings has assigned a Baa2 issuer rating for the first time to PT Danantara Investment Management , while simultaneously attaching a negative outlook in line with the outlook for Indonesia's sovereign debt rating.Moody's also assigned a Baa2 provisional rating to DIM's global senior unsecured medium-term notes  program and a Baa2 rating to DIM's proposed senior unsecured notes issuance, both of which carry negative outlooks.\"Danantara Investment Management's Baa2 issuer rating with a negative outlook is aligned with the sovereign rating of the Government of Indonesia , which is supported by strong credit linkages, including its ownership structure within Danantara's institutional framework, and our expectation of timely extraordinary support from the government,\" Rachel Chua, Vice President and Senior Analyst at Moody's Ratings, stated in an official release in Jakarta on Wednesday, June 3, as reported by Antara.","market":"hk","thumbnail":"https://statik.tempo.co/data/2025/08/24/id_1423228/1423228_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/08/24/id_1423228/1423228_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2106612/moodys-rates-danantara-investment-at-baa2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2106612/moodys-rates-danantara-investment-at-baa2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4007","BK4139","MCO","LU0390134368.USD","BK4548","BK4216","DIM","LU1043141123.HKD","BK4585","MTN","LU0426412945.USD","LU1121112475.USD","BCA.AU","SG9999001077.SGD","BK4588","BK4112","LU1043141396.HKD","GRI","LU0426417589.USD","BK4559","LU0994945656.USD","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640751913","title":"Colliers releases 2025 Global Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2640751913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640751913?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:00","pubTimestamp":1780387200,"startTime":"0","endTime":"0","summary":"Highlights emissions reductions and progress in delivering long-term valueTORONTO, June  02, 2026  (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI) released its 2025 Global Sustainability Report, demo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304880/0/en/Colliers-releases-2025-Global-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4079","GRI","BK4139","CIGI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951221","title":"Plexus Issues Fiscal 2025 Sustainability Report and Announces Transition to Absolute Emission Reduction Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951221?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317000,"startTime":"0","endTime":"0","summary":"NEENAH, WI, June  01, 2026  (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) today announced the release of its Fiscal 2025 Sustainability Report. The report, which is now available on the Sustainabili","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304353/0/en/Plexus-Issues-Fiscal-2025-Sustainability-Report-and-Announces-Transition-to-Absolute-Emission-Reduction-Targets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","LU0154245756.USD","BK4007","BK4145","BK4139","LU0154245673.USD","PLXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955428","title":"Kinross releases 2025 Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955428","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955428?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:00","pubTimestamp":1780311600,"startTime":"0","endTime":"0","summary":"Strong ongoing commitment to Sustainability, contributing $4.9 billion in economic benefits through payments to governments, wages, procurement and community supportTORONTO, June  01, 2026  (GLOBE NEW","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304183/0/en/Kinross-releases-2025-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GHG","EU","BK4532","KGC","LU1223083913.SGD","BK4142","LU1223082196.USD","LU1223082519.USD","BK4017","BK4156","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640695375","title":"GRI Bio Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2640695375","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640695375?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:38","pubTimestamp":1780310280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 06:38 ET (10:38 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677437","title":"Safe Bulkers, Inc. Announces Availability of 2025 Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677437?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:48","pubTimestamp":1780087680,"startTime":"0","endTime":"0","summary":"MONACO, May  29, 2026  (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company’s 2025 S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303825/0/en/Safe-Bulkers-Inc-Announces-Availability-of-2025-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SB","GRI","BK4563","BK4021","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484125","title":"Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484125","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636484125?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:30","pubTimestamp":1779276600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  20, 2026  (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298369/24603/en/Repligen-Announces-Publication-of-the-Company-s-2025-Corporate-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4121","LU0012050646.USD","BK4007","LU0757428866.USD","BK4139","LU1815336091.USD","RGEN","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156023867","title":"From Growth to Symbiosis: The Evolution of Chinese Corporate Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1156023867","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156023867?lang=en_us&edition=fundamental","pubTime":"2026-05-20 15:40","pubTimestamp":1779262853,"startTime":"0","endTime":"0","summary":"The \"WISH2030 Vision Conference and Sustainable Social Value Forum\" was held on May 20th. Lu Jianzhong, Deputy Director of the Sustainable Management Committee of the China Management Science...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SINA","GRI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636640398","title":"Aura Announces its 2025 Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2636640398","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636640398?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:30","pubTimestamp":1779222600,"startTime":"0","endTime":"0","summary":"ROAD TOWN, British Virgin Islands, May  19, 2026  (GLOBE NEWSWIRE) -- Aura Minerals Inc. (NASDAQ: AUGO and B3: AURA33) (“Aura” or the “Company”) announces its 6th Annual Sustainability Report showcasi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297986/0/en/Aura-Announces-its-2025-Sustainability-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PICK","JDST","BK4585","BAR","PHYS","GOLY","BGLD","BEGS","DBC","GDX","SGOL","GLD","GDXU","DUST","GDXJ","GDXY","GLDM","GOAU","AUGO","GLDY","GLL","RING","UYM","IAUI","KGLD","USG","GLTR","DGP","BTGD","DULL","GRI","DGZ","GDXD","IAUM","CEF","AAAU","DZZ","GBUG","BK4504","IGLD","SHNY","IAU","UGL","YGLD","FGDL","SGDM","JNUG","XME","OUNZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636429076","title":"GRI Bio CEO joins A.G.P. Healthcare Company Showcase fireside chat webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2636429076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636429076?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:15","pubTimestamp":1779110132,"startTime":"0","endTime":"0","summary":"GRI Bio will take part in a virtual fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026.Chief Executive Officer Marc Hertz will discuss the company’s immune-modulating pipeline, including programs in inflammatory, fibrotic, and autoimmune diseases.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL4JrqjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","BK4007","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BK4112","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","GRI","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112494482","title":"GRI Bio Reports Q1 Financials with Positive Data for Idiopathic Pulmonary Fibrosis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1112494482","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112494482?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:01","pubTimestamp":1778785279,"startTime":"0","endTime":"0","summary":"Financial Performance: Narrowed Loss and Strengthened Cash Position GRI Bio recently released its financial report for the first quarter of 2026. The data shows the company reported a net loss of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717049","title":"GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717049","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717049?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762716,"startTime":"0","endTime":"0","summary":"GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.91) by 78.89 percent. This is a 99.01 percent increase over losses of $(162.40) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52558041/gri-bio-q1-eps-1-61-misses-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717053","title":"GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717053","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717053?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:35","pubTimestamp":1778762100,"startTime":"0","endTime":"0","summary":"Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294952/0/en/GRI-Bio-Reports-First-Quarter-2026-Financial-Results-New-Data-Reinforcing-Differentiated-Profile-of-GRI-0621-in-Idiopathic-Pulmonary-Fibrosis-and-Highlights-Continued-Advancement-o.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOC","BK4007","BK4139","BK4213","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751221","title":"GRI Bio Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751221","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751221?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:26","pubTimestamp":1778711211,"startTime":"0","endTime":"0","summary":"GRI Bio Inc reports results for the quarter ended March 31 - Earnings SummaryGRI Bio Inc GRI.OQ reported a quarterly adjusted loss of $1.61 per share for the quarter ended March 31, higher than the sa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q302:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753773","title":"Gri Bio Q1 FY26 net loss narrows to $2 million from year-ago quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753773?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:25","pubTimestamp":1778703942,"startTime":"0","endTime":"0","summary":"Gri Bio reported a net loss of USD 2 million for quarter ended March 31, 2026, narrowing from USD 3.05 million year earlier.Operating loss improved to USD 2 million from USD 3.05 million as operating expenses fell to USD 2 million from USD 3.05 million.R&D expense dropped to USD 361,000 from USD 1.64 million due to completion of GRI-0621 Phase 2a trial, while G&A rose to USD 1.64 million from USD 1.41 million on higher public company costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1K2VrG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gribio.com","stockEarnings":[{"period":"1week","weight":-0.0326},{"period":"1month","weight":-0.1401},{"period":"3month","weight":-0.2521},{"period":"6month","weight":-0.773},{"period":"1year","weight":-0.9536},{"period":"ytd","weight":-0.7424}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.388047},{"month":2,"riseRate":0,"avgChangeRate":-0.328833},{"month":3,"riseRate":0,"avgChangeRate":-0.249505},{"month":4,"riseRate":0,"avgChangeRate":-0.305171},{"month":5,"riseRate":0,"avgChangeRate":-0.187187},{"month":6,"riseRate":0,"avgChangeRate":-0.246219},{"month":7,"riseRate":0.25,"avgChangeRate":-0.189746},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.299007},{"month":9,"riseRate":0.666667,"avgChangeRate":0.137892},{"month":10,"riseRate":0.333333,"avgChangeRate":0.348158},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.181412},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.344856}],"exchange":"NASDAQ","name":"GRI BIO INC","nameEN":"GRI BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GRI BIO INC,GRI,GRI BIO INC股票,GRI BIO INC股票老虎,GRI BIO INC股票老虎国际,GRI BIO INC行情,GRI BIO INC股票行情,GRI BIO INC股价,GRI BIO INC股市,GRI BIO INC股票价格,GRI BIO INC股票交易,GRI BIO INC股票购买,GRI BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction